Review: Benzylpiperazine: a drug of abuse?

  title={Review: Benzylpiperazine: a drug of abuse?},
  author={Alice Christine Johnstone and Rod A. Lea and Katie Brennan and Susan Schenk and Martin Alexander Kennedy and Paul S Fitzmaurice},
  journal={Journal of Psychopharmacology},
  pages={888 - 894}
N-benzylpiperazine (BZP) is the active ingredient in recreational `party' or `p.e.p.' pills, which are used to provide a stimulant, euphoric effect akin to that of methylenedioxymethamphetamine (MDMA, `ecstasy'). BZP predominantly affects dopamine neurotransmission in a similar fashion to known `drugs of abuse', such as methamphetamine and cocaine, which strongly suggests BZP has abuse liability. BZP is illegal in many countries including the United States of America and Australia, yet it… 

Figures from this paper

Benzylpiperazine: "A messy drug".
Update on 1-benzylpiperazine (BZP) party pills
The in vivo and in vitro studies performed in order to understand its pharmacology, toxicology and kinetics are discussed and analytical methodologies for the identification of BZP in clinical and forensic settings are addressed.
BZP-party pills: a review of research on benzylpiperazine as a recreational drug.
Recreational Drug Using Behaviour and Legal Benzylpiperazine Party Pills
Benzylpiperazine (BZP) is a stimulant drug that produces effects similar to amphetamines (Campbell, Cline, Evans, Lloyd, & Peck, 1973). It has been sold legally in New Zealand in the form of 'party
Subjective effects in humans following administration of party pill drugs BZP and TFMPP alone and in combination.
The use of piperazine derivatives, colloquially named 'party pills', has been escalating in New Zealand and worldwide since their introduction in the 1990s. Benzylpiperazine (BZP) is often used
Nephrotoxic effects of common and emerging drugs of abuse.
The nephrotoxic effects of these common and emerging drugs of abuse are discussed, of which both community and health care providers should become aware given their widespread abuse.
Designer Drug (DD) abuse in Poland; a review of the psychoactive and toxic properties of substances found from seizures of illegal drug products and the legal consequences thereof. Part II--piperazines/piperidines, phenylethylamines, tryptamines and miscellaneous 'others'.
These two articles may help suitable legislation to be rapidly devised to make the prohibition of DDs permanent whenever deemed necessary, as well as providing an up-to-date reference source for those engaged in the DD issue.
Adulthood Outcomes in Rats Following Repeated Adolescent Exposure to 1-Benzylpiperazine (BZP) and/or Ethanol.
Overall, it appeared that adolescent exposure to BZP and/or alcohol did not have long-term behavioural consequences, at least in rats, which was most likely due to the narrow range of testing ages adopted in the study.


Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts
It was concluded that 1-benzylpiperazine is a compound liable to abuse by an addict population, and that this type of study might be of value in predicting abuse liability of other new drugs.
A2 (N-benzylpiperazine) a new drug of abuse in Sweden.
N-Benzylpiperazine was tested in the beginning of the 1970s as a possible antidepressant drug. However, in both animal and human studies, it was shown to possess amphetamine-like properties, and any
N-Substituted Piperazines Abused by Humans Mimic the Molecular Mechanism of 3,4-Methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’)
The results show that BZP/TFMPP and MDMA share the ability to evoke monoamine release, but dangerous drug–drug synergism may occur when piperazines are coadministered at high doses.
Rewarding properties of 1-benzylpiperazine, a new drug of abuse, in rats.
The results show that 1-benzylpiperazine possesses rewarding properties in the rat, which suggests the compound to be susceptible to human abuse.
Chemistry, Pharmacology, Toxicology, and Hepatic Metabolism of Designer Drugs of the Amphetamine (Ecstasy), Piperazine, and Pyrrolidinophenone Types: A Synopsis
Abstract: Designer drugs of the amphetamine type (eg, MDMA, MDEA, MDA), of the new benzyl or phenyl piperazine type (eg, BZP, MDBP, mCPP, TFMPP, MeOPP), or of the pyrrolidinophenone type (eg, PPP,
Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand.
The results of this study indicate that BZP can cause unpredictable and serious toxicity in some individuals, and should be carefully considered in any discussion on the legal status of piperazine-based party pills.
Metabolism of designer drugs of abuse.
The metabolism of new designer drugs of abuse that have emerged on the black market during the last years are reviewed and papers describing identification of in vivo or in vitro human or animal metabolites and cytochrome P450 isoenzyme dependent metabolism have been considered.